This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) is considering hair loss as one possible area for future expansion as it looks beyond its core obesity and diabetes franchises, with the idea emerging alongside a broader strategy reset. Chief Scientific Officer Martin Lange said the company could apply its drug-development expertise to the hair-loss field, although it is not currently among the conditions targeted for mid-stage trials. Novo has also said some consumer-focused programs could reach the market before the end of the decade. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart The Danish drugmaker's Sept.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.